FELBAMATE

Post-LOE

felbamate

ANI Pharmaceuticals

ANDAORALTABLET

Approved

Sep 2011

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

FELBAMATE (felbamate) by ANI Pharmaceuticals is clinical pharmacology mechanism of action: the mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Approved for epilepsy, anemia. First approved in 2011.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action: The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Felbamate is effective in mice…

Worked on FELBAMATE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FELBAMATE

Mechanism of Action

Indications (2)